0001628280-23-008516.txt : 20230317 0001628280-23-008516.hdr.sgml : 20230317 20230317171421 ACCESSION NUMBER: 0001628280-23-008516 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230313 ITEM INFORMATION: Termination of a Material Definitive Agreement FILED AS OF DATE: 20230317 DATE AS OF CHANGE: 20230317 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 23743781 BUSINESS ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 8-K 1 sgmo-20230313.htm 8-K sgmo-20230313
March 13, 20230001001233false00010012332023-03-132023-03-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 13, 2023

 
 SANGAMO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
  
Delaware 000-30171 68-0359556
(State or other jurisdiction of
incorporation)
 (Commission
File Number)
 (IRS Employer
ID Number)
7000 Marina Blvd., Brisbane, California 94005
(Address of principal executive offices) (Zip Code)
(510) 970-6000
(Registrant’s telephone number, including area code) 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report) 
 
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.01 par value per share SGMO Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




Item 1.02 Termination of a Material Definitive Agreement.
Termination of Collaboration and License Agreement with Novartis
On March 13, 2023, Novartis Institutes for BioMedical Research, Inc. (“Novartis”) notified Sangamo Therapeutics, Inc. (“Sangamo”) of its termination for convenience, effective June 11, 2023 (the “Novartis Termination Date”), of the Collaboration and License Agreement (the “Novartis Agreement”) by and between Novartis and Sangamo dated July 27, 2020, pursuant to which Novartis and Sangamo were engaged in programs to research gene regulation therapies to treat three neurodevelopment disorders. Novartis has indicated to Sangamo that the termination relates to a recent strategic review. Sangamo will investigate alternative options to advance the neurodevelopmental disorder programs that were subject to the Novartis Agreement, including potential development internally or with a collaboration partner, dependent on the outcome of a broader strategic review of its pre-clinical pipeline of therapies to treat patients suffering from central nervous system (“CNS”) disorders.
Under the Novartis Agreement, Sangamo granted to Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain of its zinc finger protein transcription factors (“ZFP-TFs”), also known as zinc finger transcriptional regulators (“ZF-TRs”), targeted to three undisclosed genes that are associated with neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. Over the three-year collaboration period, which was scheduled to expire under the Novartis Agreement on July 27, 2023 in conjunction with Sangamo’s planned delivery to Novartis of ZFP-TFs for each of the three programs, Sangamo has performed early research activities for each gene target and manufactured the ZPF-TFs required for such research, the costs of which have been fully reimbursed by Novartis. Subject to certain exceptions, Sangamo has been prohibited from developing, manufacturing or commercializing any therapy targeting any of the three genes that were the subject of the collaboration, and this prohibition will terminate as of the Novartis Termination Date.
Under the Novartis Agreement, Novartis paid Sangamo a $75 million upfront license fee and Sangamo was eligible to earn from Novartis up to $720 million in milestone payments as well as tiered high single-digit to sub-teen double-digit royalties on sales of products arising from the collaboration. As of the Novartis Termination Date, the Novartis Agreement will be terminated in its entirety and Sangamo will not be entitled to any milestone payments or royalties from Novartis. In addition, as of the Novartis Termination Date, Novartis will have no further obligations to develop or to reimburse the costs of any of the neurodevelopmental disorder programs under the Novartis Agreement.
Termination of Collaboration and License Agreement with Biogen
On March 17, 2023, Biogen MA, Inc. and its affiliate, Biogen International GmbH (together, “Biogen”) notified Sangamo of its termination for convenience, effective June 15, 2023 (the “Biogen Termination Date”), of the Collaboration and License Agreement (the “Biogen Agreement”) by and between Biogen and Sangamo dated February 26, 2020, pursuant to which Biogen and Sangamo were engaged in programs to research and develop gene regulation therapies to treat neurological diseases. Biogen has indicated to Sangamo that the termination relates to a recent strategic review. Sangamo will investigate alternative options to advance the neurological disease programs that were subject to the Biogen Agreement, including potential development internally or with a collaboration partner, dependent on the outcome of a broader strategic review of its pre-clinical pipeline of therapies to treat patients suffering from central nervous system (“CNS”) disorders.
Under the Biogen Agreement, Sangamo granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain zinc finger protein (“ZFP”) and/or AAV-based products directed to up to 12 neurological disease gene targets selected by Biogen. Biogen selected four of these: Sangamo’s ST-501 product candidate to treat tauopathies, Sangamo’s ST-502 product candidate to treat synucleinopathies including Parkinson’s disease, a third product candidate targeting Type 1 Myotonic Dystrophy (DM1), a neuromuscular disease, and a fourth undisclosed neurological disease gene target. For each gene target selected by Biogen, Sangamo performed early research activities, costs for which were shared by the companies, aimed at the development of the combination of proprietary CNS delivery vectors and ZFP-TFs (or potential other ZFP products) targeting therapeutically relevant genes. For three of the four product candidates, Sangamo had achieved predetermined proof of mechanism objectives and had advanced research activities to late-stage preclinical testing with lead candidates. Sangamo’s research activities for all targets were scheduled to conclude no later than April 2027. Subject to certain exceptions, Sangamo has been prohibited from developing, manufacturing or commercializing any therapy directed to the targets selected by Biogen, and this prohibition will terminate as of the Biogen Termination Date.
Upon effectiveness of the Biogen Agreement, Biogen paid Sangamo a $125 million upfront license fee. Concurrently with the execution of the Biogen Agreement, Biogen and Sangamo entered into a stock purchase agreement pursuant to which Biogen purchased 24,420,157 shares of Sangamo’s common stock for an aggregate purchase price of $225 million. Sangamo was eligible to earn from Biogen up to $2.37 billion in milestone payments, assuming selection by Biogen of all 12 collaboration targets allowed under the Biogen Agreement, as well as tiered high single-digit to sub-teen royalties on sales of products arising from the collaboration. As of the Biogen Termination Date, the Biogen Agreement will be terminated in its



entirety and Sangamo will not be entitled to any milestone payments or royalties from Biogen. In addition, as of the Biogen Termination Date, Biogen will have no further obligations to develop or to reimburse the costs of any of the neurological disease programs under the Biogen Agreement.
As previously disclosed in Sangamo’s Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form 10-K”), Sangamo believes that its available cash, cash equivalents, and marketable securities will be adequate to fund its operations for at least 12 months from the date of its consolidated financial statements included in the Form 10-K, and does not expect the termination of the Novartis Agreement and Biogen Agreement to impact this estimate.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, statements regarding the ability of Sangamo to identify and secure alternative options to advance the programs that were subject to the Novartis Agreement and Biogen Agreement, including its ST-501 and ST-502 product candidates, whether internally or through a potential new collaboration partner; Sangamo’s broader strategic review of its development pipeline of therapies to treat patients suffering from CNS disorders; the adequacy of Sangamo’s cash, cash equivalents and marketable securities to fund its planned operations and the timing thereof; and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Sangamo’s actual results may differ materially and adversely from those expressed in these forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to: the impact of macroeconomic factors, including the effects of the COVID-19 pandemic, the ongoing conflict between Russian and Ukraine, and bank failures on the global business environment, healthcare systems and the business and operations of Sangamo and its collaboration partners; the research and development process; the manufacturing of products and product candidates; the potential for technological developments that obviate technologies used by Sangamo; the potential for Novartis and Biogen to breach their respective Collaboration Agreements; the potential that Sangamo will not be able to identify and secure options or new collaborators for programs that were subject to the Novartis Agreement and Biogen Agreement; the potential for Sangamo to cease development of these programs, whether due to its inability to secure options to bring the program forward or otherwise; Sangamo’s lack of resources to fully develop, obtain regulatory approval for and commercialize its product candidates; Sangamo’s cash position, including the risk that Sangamo’s future viability beyond one year from the date of issuance of its consolidated financial statements included in the Form 10-K is dependent on its ability to raise substantial additional capital to finance its operations; Sangamo’s ability to effectuate plans to address its liquidity needs, including cost-preservation measures, and to continue as a going concern; and Sangamo’s ability to raise additional capital on acceptable terms or at all. These risks and uncertainties are described more fully in Sangamo's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2022. The information contained in this Current Report on Form 8-K is as of March 17, 2022, and Sangamo undertakes no duty to update forward-looking statements contained in this Current Report on Form 8-K except as required by applicable laws.




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  SANGAMO THERAPEUTICS, INC.
Dated: March 17, 2023  By: /s/ SCOTT B. WILLOUGHBY
  Name: Scott B. Willoughby
  Title: Senior Vice President, General Counsel and Corporate Secretary


EX-101.SCH 2 sgmo-20230313.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 sgmo-20230313_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover page. Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Current Fiscal Year End Date Current Fiscal Year End Date Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 4 sgmo-20230313_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover Page Cover Page
Mar. 13, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Mar. 13, 2023
Entity Registrant Name SANGAMO THERAPEUTICS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 000-30171
Entity Tax Identification Number 68-0359556
Entity Address, Address Line One 7000 Marina Blvd.
Entity Address, City or Town Brisbane
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94005
City Area Code 510
Local Phone Number 970-6000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol SGMO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001001233
XML 6 sgmo-20230313_htm.xml IDEA: XBRL DOCUMENT 0001001233 2023-03-13 2023-03-13 2023-03-13 0001001233 false 8-K 2023-03-13 SANGAMO THERAPEUTICS, INC. DE 000-30171 68-0359556 7000 Marina Blvd. Brisbane CA 94005 510 970-6000 false false false false Common Stock, $0.01 par value per share SGMO NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Cover Page Sheet http://www.sangamo.com/role/CoverPageCoverPage Cover Page Cover Page Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentPeriodEndDate - sgmo-20230313.htm 4 sgmo-20230313.htm sgmo-20230313.xsd sgmo-20230313_lab.xml sgmo-20230313_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sgmo-20230313.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "sgmo-20230313.htm" ] }, "labelLink": { "local": [ "sgmo-20230313_lab.xml" ] }, "presentationLink": { "local": [ "sgmo-20230313_pre.xml" ] }, "schema": { "local": [ "sgmo-20230313.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sgmo", "nsuri": "http://www.sangamo.com/20230313", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgmo-20230313.htm", "contextRef": "i1351ad2da5f44087a8b5080ddc6d7f58_D20230313-20230313", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.sangamo.com/role/CoverPageCoverPage", "shortName": "Cover Page Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgmo-20230313.htm", "contextRef": "i1351ad2da5f44087a8b5080ddc6d7f58_D20230313-20230313", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sangamo.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001628280-23-008516-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-008516-xbrl.zip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end